Kyowa Hakko Kirin, Ultragenyx To Develop Treatment For X-linked Hypophosphatemia

Kyowa Hakko Kirin is committed to expansion, and the deal with Ultragenyx for a first-in-class therapy of a rare bone disorder is small but establishes a clinical trial foothold overseas